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Our aim was to assess if outcomes for cystic fibrosis (CF) patients at six & sixteen years of age have improved in the 
last 17 years looking at FEV1, BMI and death.  
 
Methods 




84 patients were included in the 16-year-old data and 89 patients were included in the six-year-old data. The mean 
FEV1 and BMI (16 years) for the 2002-2007 group was 72.9±21.0% and 18.9±2.53 respectively, 2008-2013 group was 
75.4±27.2% and 19.8±2.7 and for the 2014-2018 group was 95.2±16.0% and 22.9±4.1. The percentage of patients (16 
years) with chronic pseudomonas status was 37.9% (11/30) in the 2002-2007 group, 51.6 % (16/31) in the 2008-2013 
group and 4.2% (1/24) in the 2014-2018 group. The relationship between FEV1 and FVC with BMI remained significant 
in multivariate analysis (P <0.001). The mean FEV1 (six years) for the 2002-2007 group was 90.7±16.1%, 2008-2013 
group was 99.3±17.9% and for the 2014-2018 group was 100.9±15.8%. 
 
Conclusions 
Improvements in FEV1 and BMI aged six and 16 years are notable as well as a significant decline in the number of 




Cystic Fibrosis (CF) is the most common life shortening genetic condition affecting Caucasians1,2,3. There is a high 
prevalence of CF in Europe with a particularly high mean prevalence in Ireland (2.98/10,000) 4,5,6. Early diagnosis of CF 
provides opportunities for earlier medical intervention7. Lung health is a major indicator of wellbeing in CF which is 
represented by FEV1 (Forced Expiratory Volume in 1 second)7. In 2016, 250 adults (43.9%) and 47 children (8.3%) had 
chronic pseudomonas aeruginosa infection7. Prevalence of CF related diabetes in Ireland is 31.5%8. Since 2000, an 
average of 18 individuals died annually (range: 7-31)7. 
Major recent advances in Ireland include the introduction of new-born screening for CF in Ireland in 20118. 
Pseudomonas aeruginosa is an early acquired pathogen in CF patients that can lead to chronic infection, more rapid 
lung function decline and premature death3,9. To prevent these poor outcomes, early eradication of pseudomonas 
protocols have been introduced to aggressively eradicate this organism,10,11,12.  Patient segregation and isolation to 
reduce cross infection have become the standard of care13,14. The use of Ivacaftor and Lumacaftor /ivacaftor (Orkambi) 
have been a huge milestone in CF care15-18. Ireland subsequently gained access to Lumacaftor/Ivacaftor in 2017 for 
over 12 years with Delta f 508 homozygous. In February 2018, Lumacaftor/Ivacaftor was extended to the 6-11 year 
old age group and is now available to children over two years of age8.   
The aim of our project was to assess if outcomes for cystic fibrosis patients have improved in our centre since the 
introduction of these key measures over the past 17 years. We chose two time points to evaluate patients aged six 
and sixteen years of age. The timepoint of sixteen years of age was chosen as this is the age for children to be 
transferred to the adult service in our centre. Six years was also chosen so the impact of of new-born screening in 2011 





We carried out a retrospective observational study using a prospectively maintained database of cystic fibrosis 
patients in Cork University Hospital (CUH).  
The cystic fibrosis nurse specialists have maintained a record of all cystic fibrosis patients since the early 1980s 
including all patients who passed away during this time in both the paediatric and adult services. 
Approval to access the patient’s records was granted by the Cork University Hospital Clinical Governance and Audit 
Office. 
Our inclusion criteria included any child who reached 16 years of age between 1st Jan 2002 and 31st December 2018 
under the care of the CUH paediatric cystic fibrosis service were included in the 16 years of age cohort.  
Similarly, all children under the care of the CUH paediatric cystic fibrosis service between 1st Jan 2002 to 31st December 
2018 who reached six years of age during this time period were included in the six years of age cohort. 
The outcomes to be measured include; patient demographics including date of birth, date of diagnosis, reason for 
presentation, genotype and initial sweat chloride result at time of diagnosis. Lung function tests: FEV1 and FVC (Forced 
Vital Capacity) at sixteen years and six years respectively for each cohort. BMI (Body mass index) at sixteen years and 
six years for each cohort. Pseudomonas status (Leeds Criteria19) classified as never (no previous positive pseudomonas 
sputum or cough swabs), free from (a previous positive pseudomonas sample but none in over the last 12 months 
prior to transfer), intermittent (<50% of sputum samples positive in the preceding 12 months) and chronic (>50% of 
sputum samples positive for pseudomonas in the preceding 12 months). Diabetes diagnosis at sixteen or six years of 
age depending on cohort where insulin was required as part of their care (CF related diabetes defined on the basis of 
either a two hour oral glucose tolerance test blood glucose of >/= 11.1mmol/L/ fasting blood glucose of >/= 7mmol/L 
on two or more occasions or fasting blood glucose of >/=7mmol/L plus random blood glucose level of >/=11.1mmol/L 
or random BG levels of >/= 11.1mmol/L with symptoms of diabetes mellitus on two or more occasions when otherwise 
clinically well20. Also, the use of CFTR modulators and transplant status: Lung transplant undertaken prior to sixteen 
years.  
Statistical analysis using descriptive statistics followed by linear regression analysis for both univariate and 
multivariable models was carried out using Stata SE Version 13 (Stata Corporation, College Station, TX, USA) for 








In total 85 patients reached 16 years of age between 2002 and 2018; one case file was unfortunately lost to medical 
records, leaving 84 cases to analyse. The case file lost was a patient in 2002. 
We arbitrarily grouped these patients from a 17-year period into 3 groups- two six-year groups and one five-year group 
to provide greater statistical strength rather than compare each year. Group 1. 2002-2007 (30 patients), Group 2. 
2008-2013 (31 patients) and Group 3. 2014-2018 (24 patients). 
 
Table 1. Clinical and Demographic Characteristics of 16-year-old patients with cystic fibrosis, 2002–2018. 
 
Outcome Measured 2002–2007 2008–2013 2014–2018 
Mortality (No of Deaths) 5 1 2 
No of Living patients who reached 16 years n=30 n=31 n=24 
Age at diagnosis (mean) 2.0 ± 3.9 1.1 ± 2.9 3.6 ± 4.9 
BMI, kg/m2 (mean) 18.9 ± 2.5 19.8 ± 2.7 22.9 ± 4.1 
Pseudomonas status:    
Never (%) 6 (20) 2 (6.5) 5 (20.8) 
Free From (%) 2 (6.6%) 8 (25.8) 12 (50) 
Intermittent (%) 10 (34.5) 5 (16.1) 6 (25.0) 
Chronic (%) 11 (37.9) 16 (51.6) 1 (4.2) 
Diabetes (%) 1 (3.3) 4 (12.9) 4 (16.7) 
Use of CFTR modulators (%) 0 (0) 0 (0) 6 (25.0) 
Forced expiratory volume, L (mean) 72.9 ± 21.0 75.4 ± 27.2 95.2 ± 16.0 
Forced vital capacity, L (mean) 82.7 ± 18.8 81.7 ± 22.9 103.1 ± 14.9 
No. (%) of patients DeltaF508 homozygous 23/30 (76.7) 24/31 (77.4) 14/24 (58.3) 
Mortality: No of children who passed away before 16 years of age. Age at diagnosis, BMI, forced expiratory volume and forced vital 
capacity are shown as a mean ± one standard deviation. Numbers and % are shown for pseudomonas status and use of CFTR 
modulators.  
 
Table 2. Factors associated with forced expiratory volume levels in 16-year-old patients with cystic fibrosis – linear regression. 
 
 Outcome Measured Coefficient Std Error 95% CI P value 
Model 1     
 Age at diagnosis 1.21 0.71 -0.20, 2.62 0.09 
BMI 3.21 0.69 1.85, 4.56 <0.0012 
Pseudomonas status (yes)1 -15.71 5.07 -25.81, -5.60 0.0032 
Diabetes  -7.92 8.51 -24.85, 9.01 0.355 
Use of CFTR modulator 22.78 9.96 2.96, 42.60 0.0252 
Model 2     
 BMI 2.95 0.65 1.65, 4.25 <0.0012 
 Pseudomonas status (yes)1 -10.77 4.83 -20.38, -1.15 0.0292 
 Use of CFTR modulator 13.59 9.19 -4.70, 31.89 0.143 
Model 3     
 BMI 2.77 0.70 1.37, 4.16 <0.0012 
 Pseudomonas status (yes)1 -9.75 5.04 -19.79, 0.28 0.057 
 Use of CFTR modulator 11.51 9.66 -7.12, 30.73 0.237 
Features that displayed a P value less than 0.05 in univariate analyses were included in multivariable models. 
One subject was excluded from analyses due to missing values (Patient no 85-2002 case). 
Model 1: Univariate. 
Model 2: Adjusted for each other. 
Model 3: Adjusted for each other and year of data collection. 
1Either intermittent or chronic.  
2P value significant (<0.05). 
 
 
Table 1 describes the initial results of our patients who reached 16 years of age. Overall, there was a significant increase 
in FEV1 from 95.2±16.0% in the 2014-2018 group when compared with 72.9±21.0% from the 2002-2007 group. 
Similarly, BMI improved over the time frame of our study from 18.9±2.53 back in 2002-2007 to 22.9±4.1 in 2014-2018. 
From a pseudomonas viewpoint the number of patients with chronic pseudomonas infection fell significantly from 
37.9%in 2002-2007 to 4.2% in 2014-2018. Only one cohort demonstrated the effect of CFTR modulators- the 2014-
2018 cohort. 10 patient years of ivacaftor exposure and two patient years of Lumacaftor/Ivacaftor exposure in total.  
There has been only one bilateral lung transplant (performed in UK) in a patient attending our centre in this time 
period- An 11-year old male in 2015 who subsequently passed away at 13 years of age. 
Table 2 demonstrates that BMI (FEV 1: P <0.001, FVC: P<000.1), pseudomonas status (FEV1: P 0.003, FVC: P 0.017) and 
use of CFTR modulators (FEV 1: p 0.025, FVC 0.027) were all significantly related to forced expiratory volume in 
univariate models. Similar results were found for forced vital capacity data. Subsequent multivariable analysis revealed 
the relationship between FEV1 and pseudomonas status remained borderline significant (P 0.029 in Model and 0.057 
in Model 3). The relationship for CFTR modulators and FEV1 trended to an insignificant relationship (P 0.143 in Model 
2 and 0.237 in Model 3). The relationship between FEV1 and FVC with BMI remained significant in multivariable 





Table three demonstrates our results for all patients who reached six years of age between 2002 and 2018. We 
arbitrarily grouped these patients once again: Group 1. 2002-2007 (29 patients), Group 2. 2008-2013 (30 patients) and 
Group 3. 2014-2018 (30 patients). 
The mean FEV1 rose from 90.7±16.1 in the 2002-2007 group to 100.9±15.8 in the 2014-2018 group. The mean BMI for 
the 2014-2018 group was 15.5±1.0, 2008-2013 group was 16.1±1.8 and the 2002-2007 group was 16.1±2.0. Chronic 
pseudomonas rates fell once from 10.3% in 2002-2007 to 0% in 2014-2018. Only four patients (13.3%) in the 2014-
2018 group and two patients (6.7%) in the 2008-2013 group received CFTR modulators. 
 
Table 3. Clinical and Demographic Characteristics of six-year-old patients with cystic fibrosis, 2002–2018.  
 
Outcome Measured 2002–2007 2008–2013 2014–2018 
Mortality (N) 2 2 0 
No of living patients who reached six 
years 
n=29 n=30 n=30 
Time to diagnosis:    
Before or at birth (%) 7 (25.0) 10 (33.3) 13 (48.1) 
Before 1 year (%) 10 (35.7) 13 (43.3) 8 (29.6) 
Between 1–2 years (%)  6 (21.4) 4 (13.3) 1 (3.7) 
>2 years (%)   5 (17.9) 3 (10.0) 5 (18.5) 
No (%) of patients DeltaF508 
homozygous 
19/29 (65.5) 16/30 (53.3) 20/30 (66.7) 
BMI, kg/m2 (mean) 16.1 ± 2.0 16.1 ± 1.8 15.5 ± 1.0 
Pseudomonas status:    
Never (%) 17 (58.6) 10 (33.3) 13 (43.3) 
Intermittent (%) 6 (20.7) 11 (36.7) 2 (6.7) 
Free from (%) 3 (10.3) 8 (26.7) 15 (50) 
Chronic (%) 3 (10.3) 1 (3.3) 0 (0) 
Diabetes (%)  0 (0) 0 (0) 0 (0) 
Use of CFTR modulator (%) 0 (0) 2 (6.7) 4 (13.3) 
Forced expiratory volume, L (mean) 90.7 ± 16.1 99.3 ± 17.9 100.9 ± 15.8 
Forced vital capacity, L (mean) 94.1 ± 14.6 101.7 ± 15.2 102.8 ± 16.7 
Mortality: No of children who passed away before 6yrs of age. BMI, forced expiratory volume and forced vital capacity are shown 
a mean ± one standard deviation. Numbers and % are shown for time to diagnosis, pseudomonas status and use of CFTR 
modulators. 
 
Linear regression analysis was subsequently carried out on this dataset also. BMI is a strong determinant with regard 
to FEV1 (P 0.024) and FVC (P 0.031) levels in 6-year-olds although BMI levels haven't changed to a statistically 
significant level between the 2002-2007 and 2014-2018 cohorts. None of the other variables displayed a convincing 
relationship with FEV1 and FVC. Time to diagnosis was not statistically significant under univariate analysis (FEV1: P 
0.507 and FVC: P 0.575). Neither was pseudomonas status (FEV1: P 0.381, FVC: P 0.437), diabetes diagnosis (FEV1 P 





The group of patients born before the introduction of newborn screening showed no difference in the age of diagnosis 
between the different cohorts. The most likely reasons for this are that prior to newborn screening the diagnosis of 
cystic fibrosis was on the basis of characteristic clinical findings and laboratory values, and in the past the diagnosis 
was often not clear cut on an initial consultation21. Equally the age of onset of symptoms is highly variable from 
antenatal evidence of echogenic bowel to adolescent onset respiratory symptoms. A similar experience was found in 
the US in 1996 where only two states had introduced newborn screening by that time. The earlier diagnoses provided 
by newborn screening have not demonstrated an improvement in outcomes for our six-year old patients as of yet as 
only a very small minority of patients in our 2014-2018 cohort benefitted from screening. Significant Improvements in 
FEV1 and BMI are noted over the past 17 years at both six & sixteen years of age. In the past five years, our sixteen 
year old patients have reached the European Cystic Fibrosis Society (ECFS) recommendation of a BMI >20kg/m2 in 
adults with CF and matches national figures of an average BMI of 22.3 in 20168,22. BMI, pseudomonas status and use 
of Ivacaftor/Orkambi medications were all significantly related to forced expiratory volume and forced vital capacity 
levels in univariate models at sixteen years. The relationship between pseudomonas status remained significant (or 
borderline significant) in multivariable models at sixteen years, while the relationship for medication use trended to 
insignificant – but the numbers were low for this variable. A limitation to this study is that we did not collect data on 
imaging e.g. CT thorax in these patients.   
There is a huge decline in the number of patients with chronic pseudomonas at 16 years of age although the rate of 
acquiring pseudomonas infection has not changed. This may be related to changes in antibiotic prescribing including 
use of inhaled therapy leading to pseudomonas eradication. Our low chronic pseudomonas rates are in keeping with 
national figures of 8.3% from the national CF registry in 20168. Shidhani et al report that they have detected a decline 
in the overall prevalence of pseudomonas infection in their CF population which we have not detected23. The likely 
reason for this is that both studies were carried out at single centre sites which have different catchment areas in 
Ireland- we cover Munster while Children’s Health Ireland at Crumlin covers Leinster so geography may play a role. 
However, they describe a similar change in the pattern of severity of pseudomonas infection to our study with a fall in 
chronic pseudomonas rates23. We did not assess in this study whether the prevalence of multidrug resistant bacteria 
had increased during the same time frame. A further limitation to our study is its retrospective nature. Internationally, 
our chronic pseudomonas rates as per the Leeds Criteria are lower than the US at 40% in adolescents as of 201524. 
In conclusion, the real driver behind the more favourable FEV1 and FVC outcomes we are seeing in recent years are 
the more optimal BMI levels that we are observing in our patients as demonstrated by our multivariable analysis (Table 
two). It is hoped that improvements in FEV1 and BMI will translate into an improvement in the quality of life and 
longevity in this population as they enter adulthood which we hope would be a finding relevant internationally.  
This would suggest that for us to continue to see improving FEV1 and FVC levels at six years of age, a goal would be to 
increase dietetic support and nutritional supplementation during these initial formative years.  
 
Continued improvement in the outcomes aged 16 years will be accrued when the group diagnosed by newborn 
screening are assessed (aged 16 in 2027).  We look forward to seeing the outcomes in teenagers and young adults in 
those receiving CF modifiers from early infancy and early childhood and expanding the number of patients who receive 
modifier therapy.  
 
Continued investment by the Health Service Executive in the maintenance of multidisciplinary teams in designated CF 
centres as advocated in the National Model of Care for Cystic Fibrosis will be vital to provide state of the art care to 
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